Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Quanterix Corp.
Headquarters: Lexington, MA, United States of America
Website: http://www.quanterix.com
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Masoud Toloue, PhD
Number Of Employees: N/A
Enterprise Value: $747,959,960
PE Ratio: -7.6
Exchange/Ticker 1: NASDAQ:QTRX
Exchange/Ticker 2: N/A
Latest Market Cap: $273,907,808
BioCentury | Jul 12, 2024
Management Tracks
J.P. Morgan adds Joseph Siletto as managing partner
Plus: Fresenius and NS Pharma name new presidents, and updates from The Francis Crick Institute, CIRM, Nuvalent and more
BioCentury | Nov 22, 2023
Emerging Company Profile
Sunbird: blood-based diagnostics via exosomes and proteases
Singapore-based Sunbird hopes to roll out its exosome-based Alzheimer’s test in 2025
BioCentury | Nov 9, 2023
Regulation
Nov. 8 Quick Takes: FDA approves Lilly’s tirzepatide for weight loss
Plus: Takeda’s fruquintinib approved for colorectal cancer, and updates from Forward, Ascidian, Xencor, UltraDx and more
BioCentury | May 26, 2023
Management Tracks
Chair Thompson to depart Illumina in partial victory for Icahn
Activist investor gains one seat on sequencing company's board. Plus: CEO Clark steps down at Destiny and updates from
BioCentury | Apr 13, 2023
Management Tracks
SVB’s Sabow to lead HSBC tech, healthcare business
Plus: Century revamps C-suite amid CEO departure and updates from Bausch + Lomb, Gennao, Celares, Sherlock, Viridian and more
BioCentury | Aug 10, 2022
Management Tracks
New CMOs at Arcus, Enanta
Plus Lamba becomes CFO at ImmPACT, and updates from Appia Bio and Quanterix
BioCentury | Sep 28, 2021
Product Development
Alzheimer’s blood markers promise new era of clinical trials
Sensitive technologies could relieve dependence on imaging, but agreement on standards will be key
BioCentury | Jun 29, 2021
Management Tracks
Ogilvy’s Cronin joins Moderna; plus Gates Foundation, Turning Point, Quanterix, Esperion, Eikon and more
Kate Cronin will join Moderna Inc. (NASDAQ:MRNA) as chief brand officer on July 12. Cronin was global CEO at Ogilvy Health, a part of WPP plc (NYSE:WPP). Emilio Emini will become interim CEO of the
BioCentury | Mar 13, 2021
Product Development
Long COVID therapies are starting to populate a sparse pipeline
Candidate treatments are split between therapies addressing symptoms versus hypothesized drivers
BioCentury | Dec 31, 2020
Regulation
Dec. 30 Quick Takes: A first for Chi-Med; plus Orphazyme, BMS, FDA REMS, Pfizer, Astellas, Alkermes, Osmotica, Quanterix, Ampio and Novartis
Chi-Med’s surufatinib approved in ChinaChina’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda
Items per page:
1 - 10 of 49